Comments

Cellectis Stock Price, Quotes and Forecasts

Q: What sector and industry does Cellectis (CLLS) operate in?

Cellectis is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

CLLSNASDAQ

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

$1.47

-0.05-3.31%

At close: -

$1.49

0.021.36%

After Hours: 6:48 PM EDT

Cellectis (CLLS) Forecast

News Earnings Cellectis (CLLS) Options Guidance Dividends Analyst Ratings Insider Trades Short Interest

Edge Rankings

Stock Score Locked: Edge Members Only

Benzinga Rankings give you vital metrics on any stock – anytime.

Unlock Rankings

Cellectis Stock Price, Quotes and Forecasts | NASDAQ:CLLS | Benzinga

Explore Cellectis stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for CLLS.

Open	$1.51
Close	$1.47
Volume / Avg.	49.81K / 318.90K
Day Range	$1.47 - $1.60
52 Wk Range	1.10 - 2.95
Market Cap	$149.43M
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	50
Short Interest	0.6%
Days to Cover	6.68

Recent News

Cellectis Charts Course for 2025 With Boost From AstraZeneca Deal

([content-module:CompanyOverview, NASDAQ:CLLS) Cellectis S.A. (NASDAQ:CLLS) is a clinical-stage biotechnology company focused on developing 'off-the-shelf' cancer immunotherapies using gene-editing technology.

MarketBeat

Why Rubrik Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket

Avi Kapoor

Cellectis Upgraded to Buy: Here's Why

Cellectis S.A. (NASDAQ: CLLS) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.

Zacks

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Analyst Trends and Forecast

May

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.5

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Open	$1.51
Close	$1.47
Volume / Avg.	49.81K / 318.90K
Day Range	$1.47 - $1.60
52 Wk Range	1.10 - 2.95
Market Cap	$149.43M
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	50
Short Interest	0.6%
Days to Cover	6.68

About Cellectis

Sector

Health Care

Industry

Biotechnology

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologi...

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

How do I buy Cellectis (CLLS) stock?

You can purchase shares of Cellectis (NASDAQ:CLLS) through any online brokerage.

View our list of the best stock brokerages

Who are Cellectis (CLLS) competitors?

Other companies in Cellectis’s space includes: Molecular Partners (NASDAQ:MOLN), 4D Molecular Therapeutics (NASDAQ:FDMT), Voyager Therapeutics (NASDAQ:VYGR), Korro Bio (NASDAQ:KRRO) and Fate Therapeutics (NASDAQ:FATE).

What is the forecast, or price target, for Cellectis (CLLS) stock?

Cellectis has a consensus price target of $9.00.

What is the current price for Cellectis (CLLS)?

The stock price for Cellectis (NASDAQ: CLLS) is $1.49 last updated May 23, 2025 at 6:48 PM EDT.

Does Cellectis (CLLS) pay a dividend?

There are no upcoming dividends for Cellectis.

When is Cellectis (NASDAQ:CLLS) reporting earnings?

Cellectis’s Q2 earnings are confirmed for Tuesday, August 5, 2025.

Is Cellectis (CLLS) going to split?

There is no upcoming split for Cellectis.

What sector and industry does Cellectis (CLLS) operate in?

Cellectis is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.